Alexion Restructuring Deemed A Necessary Evil
The painful cuts in the workforce and HQ relocation planned by the new executive team at Alexion may be necessary for the long-term health of the company.
You may also be interested in...
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.
Alexion will target Soliris to about 3,000-8,000 US patients with ultra-rare generalized myasthenia gravis (gMG) following FDA approval. Meanwhile, the company has hired a new head of business development.